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Abstract
Background: Notch1 signaling is a cellular cascade with a fundamental role from brain development to adult brain
function. Reduction in Notch1 affects synaptic plasticity, memory and olfaction. On the other hand, Notch1
overactivation after brain injury is detrimental for neuronal survival. Some familial Alzheimer’s disease (FAD) mutations
in Presenilins can affect Notch1 processing/activation. Others report that Notch1 is overexpressed in sporadic
Alzheimer’s disease (AD). These works indicate that imbalances in Notch1 may be implicated in AD pathophysiology.
In this study, we addressed whether Notch1 alteration can be considered a hallmark of AD.
Results: Immunohistochemical analysis of Notch1 on cortical and hippocampal tissue from post-mortem patients
indicates an accumulation of Notch1 in plaque-like structures in the brain parenchyma of subjects with sporadic AD.
Further analysis shows that displaced Notch1 is associated with fibrillary tangles/plaques. Biochemical validation
confirms an accumulation of Notch1 in cytosolic brain fractions. This increase in protein is not accompanied with a
raise in the Notch1 targets Hes1 and Hey1. Examination of the cerebrospinal fluid (CSF) indicates that the full length
and truncations of the Notch1 protein are reduced in AD patients hinting at an accumulation in the brain parenchyma.
Conclusions: Our research indicates that Notch1 is significantly displaced and accumulated in fibrillary structures in
the susceptible hippocampal and cortical regions of sporadic AD patients. The dominant deposition of Notch1 in the
brain parenchyma and its general signal reduction in neurons is consistent in all the AD patients analyzed and
suggests that Notch1 may potentially be considered a novel hallmark of AD.
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Introduction
Alzheimer’s disease is the most common form of demen-
tia. The latest Alzheimer’s Disease International (ADI)
data, presented during the World Alzheimer Report 2015,
indicate that there are approximately 46 millions people
affected by dementia worldwide. This number is expected
to increase with the rising lifespan to 131.5 millions by
2050.
Alzheimer’s disease is mainly characterized by specific
hallmarks such as amyloid plaques, formed by insoluble
Aβ42 aggregates, and neurofibrillary tangles (NFTs), due
to Tau hyperphosphorylation inducing microtuble dis-
assemble. Progression of AD is staged according to the
spread of hyperphosphorylated Tau mapping the cerebral
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progression of the disease. Stages are grouped in three
general units: from healthy (I-II) to mild cognitive impair-
ment (III-IV) and finally to definite AD (V-VI) [1, 2].
According to the Braak staging of AD, hyperphosphory-
lated Tau spreads from the transentorhinal cortex (stages
I-II), to the limbic allocortex and adjacent neocortex
(stages III-IV) and finally to the neocortex affecting pri-
mary and secondary areas [3]. There are two forms of AD,
the early-onset AD, also known as familial AD (FAD), and
the late-onset AD or sporadic AD. The early-onset AD is
caused by missense genetic mutations in amyloid precur-
sor protein (APP), presenilin (PS) 1 and 2, all impinging on
APP processing and leading to an increase in Aβ42 gener-
ation [4]. FAD accounts for 5 % of the total AD cases. In
contrast, sporadic AD represents the predominant form
of the disease. The major risk factor for sporadic AD is the
genetic variant Apolipoprotein E4 (ApoE4) [5]. Further-
more, genome wide association studies have identified
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single nucleotide polimorphisms (SNPs) in genes adjacent
to the ApoE locus, which encode for proteins involved in
lipid metabolism and inflammation [6–8].
Despite the great efforts in understanding the causes of
AD, it remains largely unresolved which are the patho-
physiological triggers involved in the development of
neurodegeneration. Most studies have relied on genetic
FAD models involving APP and Presenilins’ mutations
[9] rather than addressing the sporadic form of the dis-
ease. Only most recently APP knockin mouse models
[10] as well as neuroinflammation model, by adminis-
tration of Polyriboinosinic:polyribocytidylic acid (PolyI:C)
[11] and lipopolysaccharides (LPS) [12], have been used
to investigate long-term changes recapitulating the pro-
gression of the sporadic form. In our study, we took
advantage of the mouse model of neuroinflammation
(PolyI:C) [11]. When administered prenatally, PolyI:C, a
synthetic analog of viral dsRNA, evokes a chronic neu-
roinflammatory state in the offspring accompanied by
amyloidogenic APP processing in the aged hippocampus
and a stark memory deficit [11]. Based on the late-onset
of the AD-like symptoms, this mouse model appeared
the most suitable to investigate changes in Notch1 signal-
ing, particularly, taken that this intracellular cascade has
been previously implicated in dementia [13]. The Notch
proteins are highly conserved transmembrane receptors,
with pleiotropic functions from neuronal development
to organ homeostasis. The Notch receptors are acti-
vated via ligand binding [14]. The ligand-receptor asso-
ciation dimerizes the receptor and triggers sequential
cleavages by metalloproteases (ADAM10/ADAM17) [15]
and the gamma secretase complex [16]. These proteolytic
events generate a Notch intracellular domain with nuclear
signaling potential. Notch receptors, besides activating
transcription (canonical pathway) [17], can also operate
in a non-transcriptional way (non canonical pathway)
[18] and determine their function in a context-specific
manner [19].
Among the Notch receptors, the best studied is the
Notch1 homologue. In the last two decades, several stud-
ies, using transgenic flies, mice and also rats, have demon-
strated that Notch1 displays a fundamental role in mature
brain function [20]. In the adult mammalian brain, Notch1
is highly expressed in neuronal progenitors as well as pyra-
midal neurons of the cortex and hippocampus, which are
the most sensitive to neurodegeneration. Lower levels are
also reported in glia cells [21].
In adult neural stem cells, Notch1 contributes to neu-
rogenesis and neuronal maturation. On the other hand,
in postmitotic neurons, Notch1 is involved in spinogen-
esis [22] and synaptic efficacy [22, 23]. At network level,
Notch1 can be induced and activated by an increase in
synaptic activity [22] and influences plasticity regulating
information processing.
Loss of function murine models of Notch1 share a
memory formation deficit [22, 24] and a more recent
study indicates that Notch1 is also essential for olfaction
[25]. Interestingly, olfaction and memory are brain func-
tions, that are progressively affected in dementia [26, 27]
making the case for a possible involvement of Notch1 in
the neurological deficits associated with the disease. Fur-
ther studies have indicated that, following ischemic or
epileptic injury, an aberrant increase in Notch1 expres-
sion contributes to neuronal demise [28–30] and neu-
roinflammation [31]. Moreover, Notch1 imbalances have
been reported in patients affected by Alzheimer’s disease
[32, 33], fronto-temporal dementia and Down’s syndrome
[34]. Despite there is no common consensus on whether
Notch1 signaling is augmented or reduced in dementia,
all these studies suggest a potential involvement of this
signaling pathway in the progression of the diseases. In
particular, studies on FAD have shown that mutations
in Presenilin 1 (PS1) and Presenilin 2 (PS2) can reduce
Notch signaling [33, 35]. In contrast, another report indi-
cates that, in sporadic AD, Notch1 expression is increased
[32]. Moreover, a clinical study using Samagacestat, an
inhibitor of gamma secretase, has recently failed due to
worsening of cognitive function, to be attributed most
probably to Notch1 dysfunction [36].
Based on our own studies indicating a critical balance
between physiological or pathological Notch1 functions
[20], we performed a careful comparative study of Notch1
expression, activation and signaling on post-mortem
specimen from sporadic AD patients and age-matched
controls. Our study shows that Notch1 expression is
fundamentally disrupted in AD patients with accumu-
lation in fibrillary plaques and tangles. On the other
hand, both Notch1 expression and activation are sensi-
bly reduced in neurons. Moreover, analysis of Notch1
in CSF indicates that extent of clearance of Notch1
is significantly decreased in AD patients. This is the
first study, which reports a significantly altered pattern
of Notch1 in human AD brains with potential for a
pathophysiological role of Notch1 in the progression of
AD.
Materials andmethods
Human tissue
The human samples were generously provided from the
Brain Bank for Dementia Research, Oxford, UK. We
received paraffin embedded brain sections and frozen
brain tissue from the entorhinal cortex of 5 controls and 5
sporadic AD patients. Furthermore, from a second group
of 6 non demented controls and AD patients, we obtained
paraffin embedded liver sections and frozen cerebrospinal
fluid (CSF). The use of human tissue has been approved
by the Ethical commission of the Brain Bank for Demen-
tia UK (OBB ID N. TW344 and OBB ID N. TW296) and
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the Swiss Ethical Commission of the Canton Vaud and
Fribourg (N.32514) for the use of human samples. All
experiments conducted on human tissue comply to the
WMA Declaration of Helsinki.
Animals
Floating sagittal sections from control (NaCl) and
immunochallenged (PolyI:C) mice [11] were obtained
fromDr. Knuesel (Institute of Pharmacology, University of
Zuerich). Sagittal sections were from 22 months old NaCl
(n= 2) and PolyI:C (n= 2) mice.
Cells
Human breast carcinoma cells, MDA-MB-231, express-
ing high levels of Notch1 (gift of Dr. Del Sal, University of
Trieste) were cultured in DMEM (PAA, Austria) supple-
mented with 10 % fetal bovine serum (PAA, Austria), glu-
tamine and penicillin/streptomycin (Invitrogen, USA). 12
hours before harvesting the media, the cells were changed
to a DMEM-based serum free media.
Antibodies and labeling reagents
The primary antibodies used for the chromogen immuno-
histochemistry on brain sections were polyclonal goat
anti-Notch1, which recognizes the C-terminal of the pro-
tein, 1:500 (sc-6014; Santa Cruz Biotechnology, USA)
and rabbit anti-cleaved Notch1 (NICD), 1:200 (cat. no.
2421; Cell Signaling, USA). The secondary antibodies and
the other reagents are the same as previously described
[25]. The primary antibodies for the immunofluorescence
were polyclonal goat anti-Notch1 against the C-terminus,
1:500 (sc-6014; Santa Cruz Biotechnology, USA), goat
anti-Notch1 extracellular portion, 1:500 (sc-23299; Santa
Cruz Biotechnology, USA), rabbit anti-Notch1 cytoplas-
mic domain, 1:500 (cat. no. 07-220; Millipore, USA),
rabbit anti-APP, which recognizes the C-terminal of
the protein, 1:500 (ab2073; Abcam, UK), mouse anti-
CD68, 1:150 (NBP2-29406; Novus, UK), rabbit anti-
CD68, 1:500 (sc-9139; Santa Cruz Biotechnology, USA),
rabbit anti-GFAP, 1:5000 (IS52430, Dako, USA), rabbit
anti-phosphorylated Tau, 1:500 (phospho T205/ab4841;
Abcam, UK), rabbit anti-Aβ42, 1:250 (cat. no. 8243; Cell
Signaling, USA), mouse anti-Aβ42, 1:2000 (cat. no. 05-
831-I; Millipore, USA), mouse anti-NF200, 1:500 (cat.
no. 1178709; Boehringer Mannheim Biochimica, Ger-
many). We also used Thioflavin T (ab120751; Abcam,
UK) to stain the misfolded β sheets at a concentration
of 100 mM diluted in water, following the manufacturer’s
instructions. Immunofluorescence has been also per-
formed on liver sections using goat anti-Notch1 against
the C-terminus, 1:500 (sc-6014; Santa Cruz Biotechnol-
ogy, USA), rabbit anti-Aβ42, 1:250 (cat. no. 8243; Cell
Signaling, USA), goat anti-Notch1 extracellular portion,
1:500 (sc-23299; Santa Cruz Biotechnology, USA), and
rabbit anti-Notch1 cytoplasmic domain, 1:500 (cat. no.
07-220; Millipore, USA). The primary antibodies utilized
for the western blot analysis on entorhinal cortex sections
and CSF were goat anti-Notch1, 1:500 (sc-6014; Santa
Cruz Biotechnology, USA), goat anti-Notch1 extracellu-
lar portion, 1:500 (sc-23299; Santa Cruz Biotechnology,
USA), rabbit anti-Notch1 cytoplasmic domain, 1:500 (cat.
no. 07-220; Millipore, USA), rabbit anti-phosphorylated
Tau, 1:1000 (phospho T205/ab4841; Abcam, UK), mouse
anti-PSD95, 1:1000 (sc-32290; Santa Cruz Biotechnol-
ogy, USA), rabbit anti-NeuN, 1:1000 (ab177487; Abcam,
UK), mouse anti-β actin, 1:2000 (sc-81178; Santa Cruz
Biotechnology, USA), mouse anti-Gapdh, 1:8000 (sc-
365062; Santa Cruz Biotechnology, USA). The secondary
antibodies used for the immunofluorescence were Cy3
donkey anti-goat (cat. no. 705-165-147), Cy5 donkey anti-
mouse (cat. no. 715-605-150), Cy2 donkey anti-rabbit
(cat. no. 711-545-152). All fluorescent conjugated anti-
bodies were purchased from Jackson Immunoresearch
Europe Ltd and were all diluted 1:1000. The secondary
antibodies used for the immunoblots were infrared-dye-
conjugated (IR-Dye) from LI-COR Biosciences GmbH,
Germany and were donkey anti-mouse IgG IR800 (cat. no.
926-32212;), donkey anti-mouse IgG IR680 (cat. no. 926-
68072), donkey anti-rabbit IgG IR800 (cat. no. 926-32213)
and donkey anti-goat IgG IR 800 (cat. no. 926-32214). All
IR-antibodies were diluted 1:10 000.
Immunohistochemistry
Chromogen immunohistochemistry, to detect the expres-
sion and distribution of Notch1 and its cleaved fragment
(NICD1), was done on healthy and AD patients sections.
Prior to starting the immunolabelings, human sections
were deparaffinized in xylol [3 × 10 minutes (min)] and
rehydrated in decreasing concentrations of ethanol [2 ×
100 %, 2 × 96 %, 1 × 80 %, 1 × 70 % and 2 × distilled
water for 5 min each]. After this step, human and mice
sections were treated following the same protocol. Anti-
gen retrieval was performed warming the sections with
10mM of sodium citrate buffer (pH 6), for 45 min at 65 ◦C
in a water bath. Thereafter, sections were washed 3 ×
5 min with Trizma-based solution (TBS), then 1 × 10
min with TBS containing 0.1 % Triton and then blocked
for 1 hour at room temperature (RT) with a blocking
solution (TBS containing 10 % fetal bovine serum (FBS)
and 0.1 % Triton). Primary antibodies were diluted in
TBS with 1 % FBS and 0.1 % Triton, distributed drop-
wise to cover the section and let incubating overnight
at 4 °C. Floating murine sections were incubated on a
shaker with gentle agitation, whereas human specimens
were kept inside a wet histochamber standing inside the
refrigerator. The next day, sections were washed three
times for 5 min and then incubated for 3 hours at RT
with secondary antibodies diluted in the same buffer used
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for primary antibodies. After this incubation, 3 × 5 min
washes with TBS preceeded, in some staining, the use of
Thioflavin T, which was followed by 2 × 5 min washes
with distilled water. Then the sections were incubated for
10 min with DAPI and washed for 2 × 5 min with TBS.
In the next step, the human sections, were treated with
Sudan Black B for 5 min to eliminate the autofluorescence
caused by lipofuscin accumulation in aged cells and then
dipped in 70 % clean ethanol until reaching the desired
level of staining. After, the sections were washed 2 × 5
min with TBS and mounted with an aqueous mounting
media.
Imaging quantification
Brain sections were imaged using a slide scanner
(NanoZoomer, Hamamatsu, Japan) with 40× objec-
tive and a confocal microscope (Leica TCS SP5; Leica
Microsystems GmbH, Germany) with 40× and 63×
objectives. The intensity of the Notch1 and NICD1 signals
was performed on chromogen 3,3’-Diaminobenzidine
(DAB) immunolabeling from randomly selected ROIs on
the dorsal hippocampus (CA1-CA2 region) and entorhi-
nal cortex. The Notch1 and NICD1 signals were extracted
from the mask of each neuron using TrakEM2 (Image J,
NIH, Bathesda, USA) and the signal was processed using
Matlab (Additional file 1: Figure S1A-C’). For Notch1,
pixel quantification was performed by setting the con-
straint for the brown color (brown = 50 >= red <=
255 and 20 >= green <= 100 and 0 >= blue <= 90)
within the tracked soma. The intensity of the Notch1
signal was analyzed on hippocampal (205 cells for AD
and 242 for the control group) and cortical (239 cells
for AD and 165 for the control group) neurons. For the
NICD1, ROIs were selected as for Notch1 and quantifi-
cation was performed by using the Euclidean distance
weight function of the NICD1 pixels from a refer-
ence parameter within the soma of hippocampal (187
cells for AD and 180 for the control group) and cor-
tical (141 cells for AD and 148 for the control group)
neurons. The euclidean distance is therefore inversely
proportional to the signal strength.
The plaques countings were performed using the
sections imaged with the Nanozoomer at 40× magnifi-
cation. A 4 × 6 square grid, covering an area of 12.1
μm2 was chosen as region of interest (ROI) and was
randomly superimposed on the images at a constant mag-
nification. The countings were conducted manually and
blindly for each patient and immunofluorescence stain-
ing. For the dorsal hippocampus as well as the entorhinal
cortex (Additional file 1: Figure S1D), 15 ROIs were cho-
sen. Plaques positive for Notch1, Aβ42, p-Tau, Thioflavin
T and double immunolabeled were counted. Plaques with
a diameter larger than 30 μm were considered only
(Additional file 1: Figure S1E-E”). In the liver, Notch1
intracellular and Notch1 extracellular immunoreactivity
was measured post-hoc as mean grey value in ROIs,
drawn on the perimeter of the hepatocytes. An average
of 10 ROIs in 5 randomly selected areas of the liver were
selected and analyzed per patient.
Immunoblotting
Western blot analysis was performed on whole cell lysates,
synaptosomal, cytosolic, nuclear fractions of the entorhi-
nal cortices, and cerebrospinal fluids from either healthy
controls or Alzheimer’s patients’.
Whole cell lysates
To obtain whole cell lysate, the tissue was fragmented on
dry ice and homogenized with non-ionic NP-40 buffer,
containing proteases’ inhibitors cocktail, 1:100 (3749.1,
Roth, Germany) with the addition of Pepstatin A 5mM
(2936.2, Roth, Germany) and phosphatase inhibitors, such
as Sodium Orthovanadate,1:100 (450243, Sigma-Aldrich,
USA), β-glycerophosphate disodium salt hydrate, 1:100
(G9422, Sigma-Aldrich, USA), Sodium Fluoride, 1:50
(201154, Sigma-Aldrich, USA). Briefly, the tissue was
homogenized using plastic pestels and thereafter son-
icated (Bandelin Sonopuls HD 70, Berlin), with 10/1
second pulses. Thereafter, the samples were centrifuged
at 1000 g for 10 min at 4 °C. Then, the supernatant
was transferred to a new tube. The protein concentra-
tion was measured through the BCA procedure (Roth,
Germany) and then samples were stored at −80 ◦C until
use.
Subcellular fractionation
The entorhinal cortex was homogenized with plastic pes-
tles by adding Hepes/Sucrose solution, proteases and
phosphatases inhibitors (PPI) and sonicated as above indi-
cated. After homogenization, in each tube was added
Hepes/Sucrose to have a final Vol. of 1.4-1.5 ml. Then,
samples were centrifuged at 1000 g for 10 min at 4 °C
to remove the nuclear fraction and unbroken cells (pellet,
N) from the other fractions (supernatant, S1). The pellet
was further resuspended in high-salt Hepes Buffer (5 mM
HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
300 mM NaCl and 26 % glycerol (v/v), pH 7.9). After fur-
ther homogenization with a pestel, the sample was left on
ice for 30 min and then centrifuged at 21,000 g for 25 min
at 4 °C. The resulting supernatant containing the nuclear
lysate was aliquoted and stored at –80 °C. The supernatant
(S1) from the first spin was transferred in a new tube and
centrifuged at 10,000 g for 15 min. The supernatant (S2)
was collected. The pellet (P1) was resuspended in 10 Vol
of Hepes/Sucrose buffer and centrifuge at 10,000 g for 15
min. Thereafter, the resulting pellet (P2) (crude synapto-
somal fraction) was lysed by hyposmotic shock in H2O
(200 μl ddH2O + PPI) and rapidly adjusted to 4 mM
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Hepes (200 μl Hepes + PPI) and mixed constantly for 30
min on a rotating wheel at 4 °C. The protein concentration
for the cytoplasmic component S2 and the synaptosomal
fraction P2 was evaluated through the BCA procedure
(Roth, Germany) and samples were stored until use at−80
°C.
Cerebrospinal fluid preparation
Cerebrospinal fluid samples were thawed on ice, resus-
pended in a commercial loading buffer (PCG3009, Sigma-
Aldrich, USA) and then heated either at 95 °C for 10 min
or 50 °C for 15 min [37]. 25 μl of each sample were loaded
per lane.
Western blot analysis
Brain tissue lysates or CSF were denatured using β-
mercapto-ethanol-based loading buffer. Proteins were
separated using standard electrophoresis and western blot
procedure. Depending on the molecular weight of the
protein of interest, 8–10 % custom-made gels or precast
gels 4–12 % (PCG2015, Sigma-Aldrich, USA) were used.
For the precast PAGE 4–12 % gels, a commercial run-
ning buffer was used (PCG3001, Sigma Aldrich USA).
After running, the proteins were transferred to a nitrocel-
lulose membrane (cat # 04530301, Membrane Solutions,
Germany) using a semidry transfer machine (Trans Blot
Turbo, BioRad) for the tissue samples, or a wet transfer for
the CSF. The membranes were incubated for 1 hour with
a blocking solution containing 2 % bovine serum albu-
min (BSA) (cat # 3737.2, Roth, Germany) in TBST buffer.
Afterwards, the membranes were probed, overnight, with
primary antibodies at 4 °C, with gentle agitation. The next
day, the membranes were washed 5 × 5 min with TBST,
then incubated for 1 hour, with infrared dye-conjugated
secondary antibodies (LiCOR, Germany) diluted in TBST.
The membranes were then rinsed 6 × 5 min with TBST
and let to air dry, covered by aluminum foil. Finally, the
infrared labeled proteins were revealed using an Infrared
scanner (LiCOR, Germany).
Statistical analysis
Quantification of Notch1 immunoreactivity and NICD1
expression in the soma of hippocampal and cortical
neurons was performed using unpaired Student’s T-
test. From the fluorescent immunolabeled sections, the
average number of plaques positive for Notch1, Aβ42,
Thioflavin T, or p-Tau over 15 randomly selected areas
was analysed for normality within each group. Gaussian
normal distribution of the data was confirmed using the
Shapiro-Wilk test and the Student’s T-test was subse-
quently applied. The α significance level was considered
0.05 with a p-value said to be significant when being <
0.05. The consistency of the counting for Notch1 in all
three stainings was confirmed using the Kruskal-Wallis
test. From the result, a post-hoc power analysis was per-
formed. The number of neurons showing signs of cell
cycle re-entry was counted on 10 captions obtained from
randomly selected areas in hippocampus and entorhinal
cortex from each patient. Differences between healthy
controls or AD were analyzed with one-way ANOVA. For
theWestern Blot analysis, the optical density of each band
was assessed through Image J software and normalized
with Gapdh for the cytoplasmic component (S2), with
PSD95 for the synaptic fraction (P2), with NeuN for the
nuclear partition (N) and to the healthy control bands
(CSF). A paired Student’s T-test was performed to assess
differences between healthy controls and AD samples.
Results
Notch1 is deposited in amyloid plaques
Previous studies have reported alteration in Notch1
expression in human AD patients [32, 33]. However,
there is no agreement on whether Notch1 is reduced
or increased. In this study we investigated the pattern
of Notch1 expression in post-mortem brain, CSF and
liver tissue from sporadic AD patients and age-matched
healthy controls. The average age of the AD patients
and healthy controls (CTL) was 80 ± 9.9 and 79.6 ±
9.2, respectively. Patients were of both genders. The AD
patients were staged according to the Braak Scale to an
average of 5.4 and the healthy CTLs to 1.4 (Table 1). Using
paraffin embedded sections comprising the entorhinal
cortex and the hippocampus, we performed chromogen
immunolabeling using a Notch1 antibody, which recog-
nizes the C-terminal tail (Fig. 1a and b). On the healthy
controls sections, we observed a homogeneous label-
ing of Notch1 in the soma and processes of both hip-
pocampal and cortical pyramidal neurons. On the other
hand, in the AD patients, we found that Notch1 was
delocalized to the parenchyma in plaque-like structures
(Fig. 1a and b). Moreover, Notch1 expression in neu-
rons of the CA1 hippocampal region (Fig. 1a/inserts and
Fig. 1c) and cortex (Fig. 1b/inserts and Fig. 1d) was sig-
nificantly reduced (p<0.001). Notch1 was present in dif-
ferent plaques’ formation from core to diffused aggregates
(Fig. 1a’ and b’). Plaques positive for Notch1 could also
be found in the healthy controls, but at a much lower
frequency (Fig. 1f and g). The Notch1 pattern resembled
our earlier findings using the PolyI:C mouse model of
AD [11], in which we found visible aggregates of Notch1
in the brain parenchyma of the hippocampus and cor-
tex (Additional file 2: Figure S2A-A”). Similarly to the
human AD samples, the expression of Notch1 in neu-
rons from the PolyI:C mice was generally reduced as
compared to the age-matched NaCl injected controls
(Additional file 2: Figure S2A”). In order to characterize
the Notch1 deposition and to address whether Notch1
accumulates in amyloid plaques, we performed double
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Table 1 Human specimen
Patient ID Age Sex Braak staging CERAD Tissue Applications
035/13 85 m 5 Definite AD Entorhinal Cortex IHC/WB/qPCR
016/12 64 f 6 Definite AD Entorhinal Cortex IHC/WB/qPCR
089/11 83 f 6 Definite AD Entorhinal Cortex IHC/WB/qPCR
133/12 78 m 6 Definite AD Entorhinal Cortex IHC/WB/qPCR
100/12 90 m 4 Probable AD Entorhinal Cortex IHC/WB/qPCR
1117/00 91 f 6 Definite AD Liver/CSF IHC/WB
C4295 84 m 6 Definite AD Liver/CSF IHC/WB
142/05 87 m 6 Definite AD Liver/CSF IHC/W
C4298 76 m 5-6 Definite AD Liver/CSF IHC/WB
C4130 79 f 5-6 Definite AD Liver/CSF IHC/WB
036/02 69 f 6 Definite AD Liver/CSF IHC/WB
169/11 84 f 2 Normal Entorhinal Cortex IHC/WB/qPCR
071/13 83 f 2 Normal Entorhinal Cortex IHC/WB/qPCR
136/12 77 f 1 Normal Entorhinal Cortex IHC/WB/qPCR
121/12 89 f 2 Normal Entorhinal Cortex IHC/WB/qPCR
048/12 65 f 1 Normal Entorhinal Cortex IHC/WB/qPCR
048/02 89 m 1 Normal Liver/CSF IHC/WB
1085/03 67 m 1 Normal Liver/CSF IHC/WB
053/06 71 m 1 Normal Liver/CSF IHC/WB
083/01 79 f 0 Normal Liver/CSF IHC/WB
1050/00 81 f 1 Normal Liver/CSF IHC/WB
1182/94 80 f 1 Normal Liver/CSF IHC/WB
CERAD, Consortium to Establish a Registry for Alzheimer’s Disease
fluorescent immunohistochemistry (FIHC) using Notch1
and Aβ42 antibodies. We observed that Notch1 can be
found in amyloid rosette structures mostly in a comple-
mentary pattern with Aβ42 and only scattered overlap-
ping puncta (Fig. 1e). Confirming the chromogen stain-
ing, the FIHC shows that there is a general reduction
of Notch1 immunoreactivity in pyramidal neurons of the
CA1 hippocampal region and a displacement in abnormal
aggregates (Fig. 1e). Analysis of the plaques in the dor-
sal hippocampus (CA1-CA2 region) and entorhinal cortex
(Fig. 1f and g) reveals that the majority of such aggregates
is positive for both Notch1 and Aβ42. However, a minor
portion appears positive only for Notch1 (Additional file
3: Figure S3, white arrows) or only Aβ42 (Fig. 3a’, light
blue arrows) (Fig. 1f and g). Correlation analysis indicates
that the magnitude of Aβ42 and Notch1 positive depo-
sitions is comparable in the examined areas (R = 0.98,
Hippocampus; R = 0.95, Entorhinal Cortex).
To validate the neuroinflammatory potential of Notch1
and amyloid plaques, we performed the triple immunola-
beling with the activatedmicroglia marker, CD68 (Fig. 2a–
a”). We observed that double labeled core aggregates
were always invaded by CD68-positive microglia (Fig. 2a’,
insert). Interestingly, somemicroglia were also positive for
Notch1. The presence of Notch1 in microglia was con-
firmed in the PolyI:C model (Additional file 2: Figure S2B,
white arrowhead), suggesting that an imbalance of Notch1
may increase the pro-inflammatory potential of those
cells [31, 38]. In the healthy control sections, activated
microglia were present but to a lower extent (Fig. 2a).
CD68-positive microglia were also infiltrating fibrillary-
like aggregates positive for Notch1 and Aβ42 (Fig. 2a”,
insert). As expected, the immunoreactivity for Aβ42
in the entorhinal cortex and hippocampal CA region
of healthy controls appeared very low (Fig. 2a and b).
To further address whether Notch1 deposits trigger an
astroglia reaction, we performed triple FIHCwith Notch1,
Aβ42 and the glial fibrillary acidic protein (GFAP). We
observed that, in the AD samples, core plaques positive
for Notch1 andAβ42 (Fig. 2b’) were surrounded byGFAP-
positive astroglia. Interestingly, fibrillary-like Notch1 pos-
itive aggregates were ensheated in astroglia processes
(Fig. 2b”). Several astroglia were also positive for Notch1,
both in healthy and AD sections (Fig. 2b–b”), indicating
that Notch1 function is not exclusive to neurons and may
also play a role in astrogliosis. As expected the presence of
astroglia cells in the healthy controls section was very low
(Fig. 2b).
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a
b
c
d
f
g
b’
a’
e
Fig. 1 Characterization of Notch1 expression in sporadic AD brain tissue. a–b’) Immunohistochemical analysis on hippocampus (a–a’) and
entorhinal cortex (b–b’) shows an aberrant Notch1 deposition in the brain parenchyma. Moreover, in AD patients, Notch1 labeling appears fainter in
the cell bodies and processes of cortical and hippocampal neurons as compared to healthy controls (a–b). a’-b’) Notch1 positive plaques with
different conformation either core plaques (upper captions) or diffuse distribution (bottom captions). c–d) Box plots summarizing the quantification
of Notch1 positive pixels occupying the soma of (c) hippocampal and (d) cortical neurons of AD and healthy control patients (p < 0.001 for both
regions). e) Double immunofluorescence analysis on the dorsal hippocampus indicates that, in AD tissue, Notch1 is deposited in Aβ42 positive
plaques and is decreased in neuronal soma as compared to healthy controls. Nuclei have been counterstained using DAPI. f) Bar graph showing the
counting of plaques/100 μm2, in the hippocampus, positive for Notch1, Aβ42 and double positive. g) Bar graph showing the counting of plaques
per 100 μm2, in the entorhinal cortex, positive for Notch1, Aβ42 and double positive. *= p < 0.05, **= p < 0.01. Error bars are SEM. Scale bars are
100 μm in (a) and (e), and 25 μm in (a’) and (b’)
In order to validate the presence of Notch1 in amy-
loid aggregates, we carried out the labeling of Notch1
using two antibodies directed towards the extracellular
portion of Notch1 (Notch1 extra) and the intracellu-
lar PEST domain of Notch1 (Notch1 intra) (Fig. 3a–a”).
We observed that the two antibodies had overlapping
patterns, labeling nicely CA1 pyramidal neurons in the
healthy controls (Fig. 3a). On the other hand, in the
AD samples the extracellular Notch1 intensively labeled
the processes of a neuron, which presents a condensed
nucleus with staining only for the Notch1 intracellular
domain (Fig. 3a’, white arrowhead). Moreover, the Notch1
extracellular domain antibody shows strong overlap with
Aβ42 implying that the N-terminus domain of Notch1
may be released and deposited in some (Fig. 3a’, white
arrows) but not all amyloid aggregates (Fig. 3a’, light
blue arrows). Fibrillary-like depositions were intensively
stained for Notch1 extracellular and were labeled with
Notch1 intracellular (Fig. 3a”), suggesting the presence of
the native full protein in these aggregates. Aβ42 labeling
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a
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b
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Fig. 2 Notch1 is expressed in Aβ42 positive plaques invaded by activated microglia and astroglia. a–a”) Fluorescent immunolabeling reveals that in
AD patients, Aβ42 and Notch1 are present in core plaques (arrows in a’ and magnified insert) and fibrillary-like plaques (a”) with abundant activated
microglia, CD68 positive. In (a’) a magnified insert shows a microglia (blue) ensheathed in an amyloid fibrillary Notch1 positive plaque. In the healthy
controls (a), Aβ42 and CD68 immunoreactivity is significantly lower and Notch1 labels homogeneously the neuronal soma (insert). b–b”)
Representative fluorescent immunolabeling shows that in AD patients, core plaques and fibrillary structures positive for Notch1 and Aβ42 are
invaded by GFAP positive astroglia. GFAP immunoreactivity is significantly lower in healthy controls (b) as compared to the AD samples b’-b”). Scale
bars in all panels are 40 μm
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a
a’
a’’
Fig. 3 Notch1 intracellular and extracellular domains have distinct patterns in AD brains. a–a”) Fluorescent immunolabeling indicates that the
Notch1 extracellular domain is abundantly expressed in the processes and is co-distributed with the Notch1 cytoplasmic fragment on the cell body
of healthy neurons (a). In degenerating neurons (arrowhead in a’), the extracellular domain of Notch1 is strongly expressed in the soma and process,
whereas the cytoplasmic portion of the receptor is condensed into the nucleus (arrowhead in a’). In addition, the two domains of Notch1 co-label
some Aβ42 stained plaques (white arrows in a’ and insert in a") but not all (light blue arrows in a’). Notably, the Notch1 extracellular portion is
strongly present in the amyloid fibrils, while the intracellular component is present at a lower level (a"). Scale bars in all panels are 40 μm
was more scattered on those process-like structures
and overlapped with Notch1 extracellular and Notch1
intracellular (Fig. 3a”, insert). Notch1 intracellular frag-
ment labeled several nuclei (Additional file 4: Figure S4A),
likely corresponding either to glia or degenerated neurons.
To confirm the fibrillary nature of the Notch1 aggre-
gates, we performed double counterlabelings of Notch1
immunostained sections with Thioflavin T and DAPI
(Fig. 4 and Additional file 4: Figure S4B). In AD patients,
we observed an overlap between Notch1 and Thioflavin
T in the radius of plaques, but not in their core (Fig. 4a’,
white arrows), as well as some but not all fibrillary-like
aggregates (Fig. 4a”, large white arrows). Thioflavin T
and Notch1 depositions were observed also in healthy
controls but at lower frequency in both areas (Fig. 4b
and c). Correlation analysis confirms the coincidence of
Notch1 and Thioflavin T in plaque depositions (R = 0.95,
dorsal hippocampus; R = 0.90, entorhinal cortex). To fur-
ther investigate whether Notch1 and APP, which are both
targets of gamma secretase, are present in fibrillary aggre-
gates, we performed double immunolabeling of Notch1
with APP and counterstained for Thioflavin T. We deter-
mined that Notch1 and APP are colocalized in some but
not all Thioflavin T positive structures (Fig. 4d’, white
arrows). The partial colocalization of Notch1 with APP
was previously observed in the brains of 22 months old
PolyI:C mice (Additional file 2: Figure S2C).
Notch1 localizes in NFTs
Based on the pattern of Notch1 in AD brains, we hypoth-
esized that this protein is present in fibrillary tangles.
Therefore, we performed double immunolabeling with
Notch1 and phosphorylated Tau (p-Tau) and counter-
staining with Thioflavin T. We observed a nearly com-
plete overlap of Notch1 with p-Tau in plaque-like struc-
tures (Fig. 5). As previously observed (Fig. 4a’), the core
of the plaques is stained for Thioflavin T only with
its radius positive for all the three markers (Fig. 5a’,
arrows). As expected p-Tau and Thioflavin T show low
expression in the age-matched controls (Fig. 5a). To fur-
ther validate that Notch1 is localized in dystrophic neu-
rites, we performed co-immunolabeling with p-Tau and
the heavy neurofilament, NF-200, which are the char-
acteristic components of neurofibrillary tangles (NFTs)
[39] (Fig. 5b-b’). We observed a great overlap among
the three proteins in plaques and tangles distributed
in the parenchyma of the entorhinal cortex (Fig. 5b’)
and dorsal hippocampus (data not shown). In healthy
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b
d
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c
Fig. 4 Notch1 distribution in Thioflavin T positive plaques and fibrillary aggregates. a–a”) Double immunofluorescence indicates the co-expression
of Notch1 and Thioflavin T stained fibrils in AD brains (a’-a") as compared to the age matched control (a). In non-demented patients, Notch1 is
homogeneously distributed in neurons and Thioflavin T signal is not present. b and c) Bar graphs showing the counting, of single or double labeled
plaques for Notch1 and Thioflavin T in the hippocampus (b) and in the entorhinal cortex (c). d-d’) Fluorescence immunostaining of the entorhinal
cortex for Notch1, APP and Thioflavin T shows that Notch1 is mainly localized with Thioflavin T deposits (arrows in d’ and insert) and to a lower
extent with APP in AD brains. Expression of Notch1 and APP is critically altered in AD brains as compared to healthy control tissue (d). **= p < 0.01.
Error bars are SEM. Scale bars are 50 μm in all images
controls, the three proteins are present for the major-
ity in filaments and not aggregates, with rare occur-
rence in plaques and tangles (Fig. 5b–d). The presence
of Notch1 in filamentous structures was marked also in
22 months old PolyI:C mice (Additional file 2: Figure
S2C, white arrows). Quantification of Notch1 and p-Tau
positive plaques indicates that all plaques presenting
p-Tau have positivity for Notch1 in the dorsal hippocam-
pus, but not viceversa (Fig. 5c). On the other hand, in
the entorhinal cortex the majority of p-Tau plaques have
also Notch1 (Fig. 5d). Overall, correlation analysis con-
firms the coincidence of Notch1 and p-Tau in plaque
Brai et al. Acta Neuropathologica Communications  (2016) 4:64 Page 11 of 21
a
a’
b
c d
b’
Fig. 5 Notch1 colocalizes with p-Tau in fibrillary plaques. a–a’) In the entorhinal cortex of demented patients, Notch1 costaining with p-Tau
surrounds Thioflavin T labeled plaques (arrows in a’), whereas in the healthy control (a) there is no presence of aberrant aggregates. b–b’) In the AD
cortical tissue, Notch1 is co-expressed with p-Tau in NF-200 positive neurofibrillary filaments (arrows in b’), whereas there is no apparent
colocalization in the healthy control tissue (b). c–d) Bar graphs indicating the amount of plaques either in the hippocampus (c) or in the entorhinal
cortex (d) positive for Notch1, p-Tau and double stained. *=p < 0.05, **=p < 0.01, ***=p < 0.001. Error bars are SEM. In all panels scale bars are 40μm
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depositions in both areas (R = 0.76, dorsal hippocam-
pus; R = 0.82, entorhinal cortex). Furthermore, in all
analysis performed in the regions of interest, we observe
that Notch1 positive plaques tend to be supranumerous to
the plaques positive for p-Tau (Fig. 5c and d), Thioflavin
T (Fig. 4b and c) or Aβ42 (Fig. 1f and g). This can be
explained by the fact that Notch1 can be found in a variety
of depositions as well as cellular species. Yet, it remains
possible that Notch1 aggregates hallmark a novel type of
plaques or label protein deposits following neuronal
demise. Besides the appearance of Notch1 in aggre-
gates disseminated in the brain parenchyma, we could
observe that, in AD, the majority of the degenerating
neurons expressing high levels of p-Tau were also posi-
tive for Notch1 (Fig. 6a’). This overlap was also present
in scattered neurons from the healthy controls (Fig. 6a).
Evidence of ongoing neurodegeneration in the double
positive Notch1 and p-Tau neurons is indicated by the dis-
placement of NF-200 to the cell soma (Fig. 6b). Similarly
to the appearance of Notch1 in NFTs, the three proteins
colocalize indicating that Notch1 is also accumulating in
the dying neurons (Fig. 6b, insert). Analysis of the degen-
erated neurons, as indicated by the presence of p-Tau,
show also an accumulation of Notch1 in both dorsal hip-
pocampus (Fig. 6c) and cortex (Fig. 6d). Furthermore, in
the entorhinal cortex, we observed the presence of Notch1
protein in neurons with polynucleate morphology in both
AD (1.6 % ± 0.6) and control samples (0.7 % ± 0.3) (p =
0.2) (Additional file 5: Figure S5A and B). The number
of neurons with polynucleate morphology tended to be
a
b
c d
a’
Fig. 6 Intracellular depositions of Notch1 and p-Tau are increased in AD degenerating neurons. a–a’) Double immunostaining showing the
enhanced number of damaged neurons labeled with p-Tau and partially with Notch1 in AD and healthy control cortical tissue. b) Triple staining
showing the co-expression of Notch1 and p-Tau in neurofilament positive degenerating cortical neurons (insert). c–d) Bar graphs indicating the
counting of degenerating neurons positive for p-Tau or double positive for p-Tau and Notch1, either in the hippocampus (c) or in the entorhinal
cortex (d). *=p < 0.05, **=p < 0.01, Error bars are SEM. Scale bar in (a’) is 100 μm and in (b) 40 μm
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higher in the AD patients, but did not reach significance
(F1,8= 1.55, p = 0.2). On the other hand, the percentage of
polynucleate neurons in the CA pyramidal layer was indis-
tinguishable between AD and controls. The localization
of Notch1 in those cells suggests, as previously described,
that Notch1 may be involved in cell cycle re-entry [30], a
mechanism underlying progressive neurodegeneration.
Notch1 levels, but not activation, are increased in AD
In order to assess the expression of Notch1 in the AD
brain tissue, we conductedWestern Blot analysis on whole
cell lysates as well as crude synaptosomal, cytosolic and
nuclear fractions from entorhinal cortices. In the whole
cell lysate preparation, we observed an increase in p-Tau in
the AD samples (Normalized OD: 4.5 ± 1.8) as compared
to the age-matched controls (OD: 1 ± 0.2) (p = 0.04)
(Fig. 7a). However, Notch1 levels appeared unchanged,
as detected by two antibodies: one recognizing the
C-terminal tail (Normalized OD: 1 ± 0.7 versus 0.8 ±
0.2; p = 0.9 ) and another one against the extracel-
lular domain (Normalized OD: 1 ±0 .3 versus 1.5 0.7;
p = 0.49 ) (Fig. 7a). Being Notch1 expressed by a variety
of cells populations in the brain and in different cellu-
lar compartments, it remained possible that alteration
in Notch1 localization could be observed using cellular
fractionations. In the synaptosomal membrane fractions,
Notch1 levels as measured by the 100KDa band appear
unchanged, whereas p-Tau was increased (Fig. 7b and c).
In contrast, in the cytosolic compartment we observe an
increase in both Notch1 and p-Tau in ADs as compared
to healthy controls (Fig. 7d and e), suggesting that the
turnover of both proteins is affected in AD. Interestingly,
in the nuclear fraction, the 100KDa band corresponding to
the Notch1 intracellular domain (NICD) is represented at
a
d
b
c
f
e g
Fig. 7 Notch1 levels in the entorhinal cortex of AD patients. a) Representative Western Blot analysis on whole cell lysate indicates no difference in
Notch1 levels, represented by the extracellular and the intracellular component, between healthy controls and AD patients. In contrast, p-Tau is
increased in AD lysates. b–e) Western blot on synaptosomal fractions shows the unchanged expression of Notch1 in the synaptic (P2) component
(p = 0.2) of AD samples as compared to the controls (b and c). On the other hand, in the cytoplasmic compartment (S2) Notch1 levels are increased
(p = 0.007) in AD samples as compared to the controls (d and e). In addition, in both fractions, the levels of p-Tau are augmented in AD samples,
(P2, p = 0.02; S2, p = 0.002) as compared to the age matched controls (c and e). f–g) Immunoblotting (f) and bar graph (g) on nuclear fraction
indicates no difference in Notch1 expression between AD and healthy controls (p = 0.25). *=p < 0.05, **=p < 0.01. Error bars are SEM
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very low levels in both healthy controls and AD samples.
(Fig. 7f and g). To further explore the extend of Notch1
processing in neurons, we performed IHC using an anti-
body specific for the cleaved Notch1 and quantified the
signal in the soma of cortical (Fig. 8a) and hippocampal
neurons (data not shown). We observed that NICD was
considerably lower, showing higher euclidean color dis-
tance, in the neurons from the AD patients as compared to
the healthy controls (p < 0.001 for both regions) (Fig. 8b
and c). Furthermore, the levels of canonical target genes,
Hes1 and Hey1, and indirect targets BDNF from RNA
obtained from whole tissue preparation were indistin-
guishable between ADs and CTLs (Fig. 8d). This suggests
that overall Notch1 signaling is not increased in the brains
of AD patients. On the other side, from our whole cell
preparation, we observe a 30 % increase in Notch1 tran-
scripts, which is near to significance (p = 0.06) (Fig. 8d).
This may reflect an imbalance in Notch1 in more than one
cell type in the AD brains.
Notch1 levels are reduced in the CSF of AD patients
It is established that a variety of proteins are cleared
from the brain into the cerebrospinal fluid [40]. When the
proteins start accumulating into the brain parenchyma,
filtration through the CSF is reduced. As a result in
AD patients many proteins, with the exception of Tau,
a
b c
d
Fig. 8 Notch1 signaling in AD patients. a) Immunohistochemistry using an antibody specific for NICD1 shows that in AD cortices the activation of
Notch1 in pyramidal neurons is lower as compared to the healthy controls (inserts). b–c) Box plots summarizing the NICD signal shows a significant
difference in immunoreactivity in (b) hippocampal and (c) cortical neurons between AD and healthy CTLs. d) Bar graph showing the fold change in
transcript levels of Notch1 and some target genes, such as Hes1, Hey1 and BDNF. Only the mRNA of Notch1 is near to significance (0 = p = 0.06).
Error bars are SEM. Scale bar in (a) is 50 μm
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which is overexpressed in tangles, are reduced. In our
study, we investigated whether Notch1, which aggregates
in plaques and NFTs, is subject to differential clearance
in AD patients versus age-matched controls. Using two
different antibodies recognizing the extracellular and the
intracellular domain of Notch1, as well as the supernatant
from the human breast cancer cell lines (MDA-MB-231)
as control, we observed that Notch1 is present in CSF
and cellular supernatant in various forms. Specifically, we
detected: i) the full length protein around 250KDa, ii)
truncation forms between 72KDa and 55KDa in both CSF
and cellular supernatant, whereas the iii) small fragments
around 28KDa were only present in the CSF (Fig. 9a). This
suggests that Notch1may be released or leaked out as pro-
teolytic fragments. All these protein forms are reduced
in AD samples as compared to healthy controls (Fig. 9b).
Presence of the full length protein or the extracellular
domain is confirmed by the blot using the antibody spe-
cific for the extracellular domain (Fig. 9c) and could be
identified as a band between 130 and 250KDa, as well
as additional bands around 55 and 33KDa. The signal
ratio between the controls and AD indicates that Notch1
extracellular portions are reduced in AD as compared to
controls (Fig. 9d). These data suggest that in the CSF
several fragments of Notch1 are present and that there
is depletion of those protein species in the CSF of AD
patients as compared to healthy controls.
Notch1 aberrant expression in AD livers
To further investigate whether the accumulation in the
brain correlates with peripheral alteration in Notch1
turnover, we performed immunohistochemical analysis
on liver sections from AD and healthy patients com-
paring Notch metabolism with amyloid processing. The
presence of Notch1 and Aβ42 depositions was visible in
the liver parenchyma of 3 out of 5 AD patients (Fig. 10a,
white arrows). Hepatocytes surrounding the extracellular
plaques showed overexpression of Notch1 (Fig. 10a, white
arrowheads). Plaques were seen in sections revealing a sig-
nificant increase (more than 2 folds) in Notch1 expression
and activation, as indicated by the Notch1 extracellular
and Notch1 intracellular labelings, respectively (Fig. 10b)
(p < 0.05 for both labelings). Box plot analysis indi-
cates the distribution of Notch1 extracellular (Fig. 10d)
and Notch1 intracellular (Fig. 10c) domains in AD and
healthy controls. These results suggest that, similarly to
Aβ42, alteration of Notch1 in the liver may contribute to
plaque formation peripherally. These aberrant peripheral
a
c
b
d
Fig. 9 Notch1 fragments are less represented in the CSF from AD patients. a) Immunoblotting on CSF reveals that the full length (FL) of Notch1 is
decreased in AD samples as compared to healthy controls. Moreover, other fragments of the protein around 55 and 28 KDa appear decreased in AD
samples. b) Bar graph showing the pattern of expression of Notch1 FL and the smaller fragments in AD samples as compared to healthy controls.
c) Immunoblotting on CSF showing the diminished level of the extracellular portion of Notch1 in AD samples as compared to age matched controls.
Also with this antibody we detected fragments, either around 55 or 28 KDa, which are reduced in AD CSF. d) Bar graph showing the reduction of
Notch1 extracellular domain and the smaller truncations of the receptor in AD samples. *=p < 0.05, **=p < 0.01, ***=p < 0.001. Error bars are SEM
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Fig. 10 Altered Notch1 expression and deposition in the liver of AD patients. a-b) Immunofluorescence on liver sections. a) Notch1 and Aβ42
positive aggregates (arrows) in the hepatic parenchyma of AD patients, but not in controls. Moreover, Notch1 is highly expressed in the cytosol of
several hepatocytes (arrowsheads). b) Antibodies specific for the extracellular and intracellular portions of Notch1 strongly label hepatocytes in the
AD liver as compared to the healthy control section. c) Box plot summarizing the mean grey value intensity of the Notch1 intracellular signal in AD
and CTL hepatocytes. d) Box plot summarizing the mean grey value intensity of the Notch1 extracellular signal in AD and CTL hepatocytes. The
scale bars are in (a) and (b) 50 μm
aggregates could represent a natural sink for misfolded
proteins [41] including Notch1.
Discussion
In this work, we show for the first time that Notch1 accu-
mulates in fibrillary plaques and is remarkably associated
to NFTs in the brains of sporadic AD patients. Simi-
larly, in the neocortex of PolyI:C mice, which recapitulate
aspects of sporadic AD [11], we observe a progressive
accumulation of Notch1 in the brain parenchyma. In
both demented patients and PolyI:C mice, Notch1 depo-
sitions show a neuroinflammatory response characterized
by the presence of reactive microglia. Such delocaliza-
tion of Notch1 to plaques and tangles is concomitant
with a reduction in Notch1 expression and activation in
cortical and hippocampal neurons. Moreover, a consis-
tent reduction in Notch1 protein levels is detected in
the CSF from AD patients as compared to healthy con-
trols. This suggests a retention of the protein in the brain
milieu. Last, we provide evidence of an accumulation of
Notch1 in amyloid plaques’ formations in the liver, which
may represent a repository contributing to the progres-
sive neurodegeneration. Despite the limited number of
specimen used in this study, the results are strikingly
consistent within each group and indicate that Notch1
aggregations may be considered an additional hallmark
of AD.
Notch1 association to NFTs
Cytoskeletal integrity and plasticity is determined by
the constant turnover of proteins associated to micro-
tubules such as Tau. In AD, the cytoskeletal structure
is strongly destabilized by the overwhelming abundance
of phosphorylated Tau, which collapses axonal integrity
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and contributes to the relocalization of Tau from the
axonal to the somatodendritic compartment. Moreover,
transynaptic diffusion of Tau protein is thought to under-
lie the progressive spread of NFTs in the brain [42]. In
this study, we observed that Notch1-positive aggregates
highly correlate with NFTs as well as amyloid neuritic
plaques. The colocalization of Notch1 and p-Tau is also
found in healthy controls, but at considerable lower rate
as compared to AD patients. This suggests a functional
interaction between the Notch1 membrane receptor and
microtubules-associated proteins, as previously proposed
[43, 44]. Studies on primary cortical neurons have shown
that Notch regulates neurites’ extension and morphology
[45, 46]. In addition, it was shown that Notch activation
favors microtubules stabilization, reduction of neurite
arborization and varicosities, whereas Notch1 inhibition
can revert these events promoting cytoskeletal plasticity
[44]. Interestingly, one of the critical protein in balancing
Tau turnover is Pin1 [47, 48], a direct target of Notch1 in
breast cancer cells [49, 50]. Our own unpublished stud-
ies confirm the dependence of Pin1 on Notch1 activity
and show that hippocampal neurons devoid of Notch1
display reduced Pin1 levels along with an increase in
Tau phosphorylation (data not shown). Notably, the accu-
mulation of Notch1 in NFTs, in AD patients, does not
correlate with increased signaling but rather the oppo-
site, as indicated by reducedNICD1 in pyramidal neurons.
Thus, it is possible that a dysfunction in Notch1 sig-
naling may contribute to microtubule instability through
Pin1. It remains to be understood how and why the full
membrane receptor accumulates in NFTs and whether
this interaction contributes to cytoskeletal disassembly.
Overall, our observations suggest that Notch1 delocal-
ization to NFTs may have significant implication for
neurodegeneration.
Notch1 signaling is reduced in AD neurons
One of the late symptoms of AD is represented by
the memory impairment, the progressive disability in
speaking and altered behavior. It is established that hip-
pocampal plasticity, which is essential for memory and
emotions, is strongly affected in AD. One of the main
transduction pathways contributing to memory estab-
lishment is Notch1. This signaling receptor is highly
expressed in principal neurons belonging to neuronal
networks involved in information processing [25] and
memory formation [22, 24]. Loss of Notch1 from flies to
rodents’ brains affects memory and learning [51]. Fur-
thermore, recent work from our own group has shown
that Notch1 interacts with ApoER2 and NMDAR, which
are critical mediators of synaptic plasticity with an estab-
lished role in AD progression. Through this interaction,
CREB-dependent signaling is facilitated and contributes
to the molecular basis of memory formation [52]. These
studies, hint at a possible involvement of Notch1 signaling
in the memory demise characterizing AD. To corrobo-
rate this hypothesis, our own study shows that Notch1
levels and activity are significantly reduced in principal
neurons of the hippocampus and cortex. The absence
of a reduction in canonical targets, Hes1 and Hey1,
could be explained by the analysis conducted on whole
cell tissue preparations including both neurons and glia.
Overall, downregulation of Notch1 may impact synap-
tic plasticity and affect downstream effectors of memory
[51]. These results support the notion that dysfunction
in Notch1 expression/activity in AD may contribute to
the displacement/accumulation in plaques or NFTs and
reduced signaling in neurons.
Notch1 aggregates may contribute to neuroinflammation
Several studies suggest that one of the main contributing
factors to the onset and the progression of AD is neuroin-
flammation. The first stages of sporadic AD are triggered
by an excessive or chronic inflammatory stimulus, which
induces an increase in misfolded proteins, a reduction in
their clearance and a destabilization of microtubules. This
event impairs the physiological cellular trafficking along
the axonal processes, causing an aberrant accumulation of
proteins and other molecules in the axons length, form-
ing swollen areas known as “axonal varicosities” and a
leakage of these proteins from the axonal compartment
to the brain parenchyma [53]. Leaked proteins further
cause neuroinflammatory responses triggering progres-
sive astrogliosis and microgliosis in the interested area
[53]. In our study, we observe that, in AD patients, Notch1
depositions in the brain parenchyma are surrounded by
glial cells suggesting that Notch1 may be released from
neurons and contribute to the neuroinflammatory events
aimed at protein clearance [54]. Moreover, Notch1 can be
found in both glial types suggesting an involvement of this
pathway in the modulation of the inflammatory activity. It
is reported that all the Notch components are expressed
and active in microglia and the Notch pathway modulates
the inflammatory potential of these cells [31, 38]. Inter-
estingly, in the PolyI:C model of neuroinflammation, acti-
vated microglia are also positive for Notch1 hinting at an
ongoing inflammatory process. On the other hand, in AD
brains, astroglia is characterized by high level of nuclear
Notch1, which is a well established proliferative factor for
astrocytes [55]. This implicates Notch1 signaling in pro-
gressive astrogliosis occurring in AD. Thus, in the CNS,
Notch signaling components are expressed in different
cellular populations: i) neurons, which express both ligand
and receptor proteins [21, 22], ii) astroglia, which mainly
present the ligand Jagged1 [21] and iii) microglia, which
abundantly express Notch1 [56]. This evidence suggests
a complex interplay among different cell types within the
brain. Such mechanisms, which need to be yet uncovered,
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underlie the importance of Notch activity in modulating
brain homeostasis. Hence, an impairment in this cas-
cade may disrupt the cellular crosstalks and contribute
to an uncontrolled inflammatory response observed
in AD.
Evidence of Notch1 alteration in the CSF of AD patients
One of the diagnostic methods to detect and mon-
itor the progression of AD is the sampling of CSF.
Despite the variety of proteins, which are present in
the CSF [40], the best characterized markers are Aβ42
and Tau [57]. The measurement of the ratio between
the two proteins establishes the advancement of the dis-
ease. Typically, when Aβ42 is accumulated in plaques,
as AD progresses, levels in the CSF decline. On the
other hand, neuronal demise contributes to the release
of Tau in the CSF. Based on the evidence that Notch1
accumulates in plaques, we addressed whether levels in
the CSF were changed in AD as compared to healthy
controls. We observed that Notch1 is present in the
liquor as full protein, extracellular fragment and smaller
truncations around 55KDa and 28KDa. Former stud-
ies have detected the presence of transmembrane pro-
tein species, like APP and Presenilin1, in the CSF
[37, 58]. Interestingly, extrusion of Notch1 as full recep-
tor and extracellular portion could be also observed in the
supernatant of human breast cancer cells. This indicates
that either exocytosis of transmebrane proteins through
exosomes is constitutive of mammalian cells or that such
proteins are freed from dying cells. Moreover, smaller
truncations of Notch1 were observed in the CSF sam-
ples only. Interestingly, a circulating proteosome has been
recently detected both in plasma and CSF [59, 60]. This
raises the possibility that Notch1 may undergo proteoly-
sis at specific sites. Alternatively, those fragments could
represent insoluble aggregates of misfolded Notch1 pep-
tides. It has been previously shown that FAD mutations
of Presenilins can generate longer Nβ peptides with more
lipophylic properties [61]. It remains possible that, in spo-
radic AD, a dysfunction in gamma secretase activity, can
lead to an increase of Nβ lipophylic species, which have
the potential to form insoluble aggregates. Nevertheless,
independently of the size of the fragments, all Notch1
forms were consistently less represented in the CSF of AD
patients. This supports the notion that Notch1 is accumu-
lating in the brain and may contribute to aberrant protein
aggregates.
Aberrant Notch1 in the liver of AD patients
Clearance of misfolded protein occurs both centrally and
peripherally. The liver represents the principle site of
peripheral clearance and it is reported that in AD such
mechanism is affected [62]. Aβ42 fragments and possi-
bly other lipophylic peptides can cross the blood-brain
barrier (BBB) by binding to the lipoprotein receptor-
related protein 1 (LRP1) and the very-low density lipopro-
tein receptor (VLDLR), which export these peptides from
the brain to the blood and finally to the liver. In oppo-
site direction, the receptor for advanced glycation end
products (RAGE) determines the passage of Aβ42 from
the blood to the brain [62]. In AD, the levels of the pro-
teins involved in the efflux of Aβ42, from the brain to
the blood, are decreased, while the expression of RAGE
is increased, reinforcing the hypothesis on the primary
role that peripheral clearance has in the removal of Aβ
species [63]. Moreover, in the liver, the hepatic isoform
of LRP contributes to the elimination of these aberrant
peptides, involving several proteases including the insulin
degrading enzyme (IDE) [64]. Interestingly, IDE has been
identified as an indirect target of Notch1 [65]. All Notch
receptors and ligands are expressed in the liver and Notch
signaling plays a fundamental role in the metabolic home-
ostasis and is aberrantly induced in obesity-related liver
diseases [66]. Based on these evidences, we investigated
whether Notch1 was differentially expressed in the liver
of sporadic AD patients. We show that Notch1 local-
izes in amyloid deposits in the hepatic parenchyma and
that such aggregates are surrounded by hepatocytes with
increased Notch1 expression. In the same patients, a gen-
eral increase in Notch1 expression/activity was detected
in the liver. Previous studies indicate that insulin resis-
tance, as in diabetes, can increase Notch1 signaling [66].
Moreover, a mechanistic interaction between Notch and
insulin signaling has been previously reported [67–69].
Notably, there is a strong correlation between diabetes and
AD [70] and insulin-resistance is though to be one of the
major risks for developing dementia [71]. Thus, it is pos-
sible that progressive alteration in insulin turnover in the
liver causes Notch1 over-activation with aberrant release
of Notch1 fragments. These speciesmay lead to peripheral
plaque formation and contribute to a sink in misfolded
protein, including Notch1, which could be recycled to the
brain.
Conclusions
This study sparks unprecedented evidence of an involve-
ment of Notch1 in sporadic AD. In the human brain
tissues examined, entorhinal cortex and dorsal hippocam-
pus, we observed a profound delocalization of Notch1
from neurons to extracellular aggregates and NFTs. It
remains to be established whether this phenomenon
extends to other brain regions and whether it follows the
spread of fibrillary tangles according to the Braak stag-
ing. Yet, the present data suggest that Notch1 may be
involved, as previously described from flies to mammals,
in cytoskeletal integrity and plasticity and participates,
if altered, to neurodegeneration. In contrast, the levels
of Notch1 in pyramidal neurons of the hippocampus
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and cortex were significantly reduced implicating that
loss of Notch1 in neurons may have effect on synap-
tic plasticity and memory processes, which are signifi-
cantly impaired in AD. Moreover, we demonstrate that
Notch1 is cleared in the CSF and that such clearance,
similarly to Aβ , is drastically reduced in AD patients
suggesting an accumulation of Notch1 in the brain
parenchyma. Finally, we provide preliminary evidence
for a peripheral accumulation of Notch1 in the liver in
amyloid aggregates accompanied by an aberrant increase
of Notch1 in hepatocytes. All together these data sug-
gest that Notch signaling may be considered among the
critical pathways involved in the pathobiology of sporadic
AD. A further comparative analysis of Notch1 expres-
sion/processing in different neurodegenerative diseases
in humans is necessary to establish whether Notch1
may be considered a specific therapeutical biomarker
for AD.
Additional files
Additional file 1: Figure S1. Schematics for immunohistochemistry
analysis. A-C’) Workflow of the analysis performed to quantify the
chromogen signal of Notch1 and NICD1 in neurons. A) Representative
image of a brain tissue slice stained for Notch1 and counterstained with
Nissl displays, for clarity, marked boundaries of the ROIs analyzed in the
study [red= dorsal hippocampus (CA1-CA2 regions) and green = entorhinal
cortex]. B) Example of randomly selected area from the entorhinal cortex,
which was imported in TrakEM2. Neuronal somas selected for analysis are
highlighted in yellow. B’) Representative mask of the selected cells
obtained with TrakEM2 and imported into Matlab. C) Processed signal of
Notch1 in a pyramidal neuron is colorized in green. C’) Corresponding
histogram representing RGB color thresholds as assigned by the program.
D-E") Workflow of the analysis performed on immunofluorescent stained
sections to quantify the number of plaques and neurons positive for
Notch1 and other markers. D) Representative image of a brain section
fluorescently labeled for Notch1, p-Tau and counterstained with DAPI.
Marked boundaries indicate the ROIs analyzed [red= dorsal hippocampus
(CA1-CA2 regions) and green = entorhinal cortex]. E) Example of a
randomly selected area from the cortex divided in 24 squares (100
μm2/each), in which the countings were carried out for the analysis. Area
splitted according the fluorophore corresponding to E’) Notch1 and E")
p-Tau. Scale bars in A and D are 5 mm and in E-E" 100 μm. (PDF 1,326 kb)
Additional file 2: Figure S2. Ectopic Notch1 expression in the brain of 22
months old PolyI:C mice. A-A") Brain sections from aged mice, injected
prenatally either with NaCl or PolyI:C are immunolabeled with Notch1. A)
Notch1 expression is increased in the brains of the PolyI:C mice. A’) Zoom
in of the hippocampal formation shows visible clumps positive for Notch1.
A") Larger magnification of the CA3 field shows a disrupted pattern of
Notch1 expression in the neurons and Notch1 positive aggregates in the
molecular layer in PolyI:C mice. B) Double immunofluorescence for Notch1
and the activated microglia marker, CD68, shows that, in PolyI:C mice,
microglia are more abundant as compared to the age-matched controls
and are intensively labeled for Notch1 (white arrowhead). C) Triple
immunofluorescence staining for Notch1, APP and CD68 shows that
Notch1 expression displays a different pattern in PolyI:C mice as compared
to the controls. Moreover, Notch1-APP positive plaques (arrowheads) are
surrounded by CD68-positive microglia (insert of a 4 fold magnification of
the plaque on the right). Notch1 immunoreactive processes (arrows) are
strongly labeled in the CA1 field of PolyI:C mice. Cx= cortex The scale bars
are in A 1 mm, in A’ 500 μm, in A" and C 50 μm and in B 25 μm.
(PDF 2825 kb)
Additional file 3: Figure S3. Distinctive patterns of Notch1 deposition in
the brain parenchyma. Labeling of Notch1 (red) and Aβ42 (green) from an
entorhinal cortex of an AD patient shows some Notch1 aggregates with no
positivity for Aβ42 (white arrows). On the other hand, Notch1 (red)
decorates the majority of Aβ42 plaques (light blue arrows). The scale bar is
40 μm. (PDF 274 kb)
Additional file 4: Figure S4. Notch1 expression in fibrillary structures in
the cortex. A) Variation of Fig. 3a": double immunolabeling for Notch1
intracellular and Notch1 extracellular shows that the two Notch1 domains
overlap in fibrillary aggregates, whereas nuclei, as indicated by DAPI, are
highly immunoreactive for the cytoplasmic form of Notch1. B) Labeling of
Notch1 and Thioflavin T shows that, in AD patients, Thioflavin T positive
fibrils are also marked for Notch1. Expression of Notch1 in the healthy
controls is cytoplasmic and devoid of any Thioflavin T staining. The scale
bars are in A 40 μm and in B 100 μm. (PDF 757 kb)
Additional file 5: Figure S5. Notch1 localization in neurons with
polynucleate morphology. A) Chromogen immunolabeling shows that
Notch1 intensively labels dividing neurons, as indicated by Nissl staining,
highlighting the polynucleate morphology. B) Bar chart summarizing the
countings of dividing cells in the hippocampus and cortex shows no
significant difference between controls and demented patients. The scale
bar in A is 5 μm. (PDF 506 kb)
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